Home Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx
 

Keywords :   


Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx

2013-12-03 00:36:37| Biotech - Topix.net

ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.

Tags: of million rx pharmaceuticals

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.07Hurricane Beryl Update Statement
01.07Summary for Hurricane Beryl (AT2/AL022024)
01.07Beckers Group Announces Leadership Changes
01.07Pixellot powers Top Hockey League's new OTT viewing platform
01.0744p selects Harmonic for UHD playout, media processing and distribution
01.07Dailymotion integrated into NetRange's in-car video solution
01.07X-Rite wins PRINTING United Alliance 2024 Pinnacle Product Award
01.07Hurricane Beryl Update Statement
More »